Imbioray is a clinical-stage innovative biopharmaceutical company, the pioneer of generic off-the-shelf trained-immunity NK cells, dedicated to the research, development, and clinical application in the cell field. It has achieved comprehensive applications of ACC-NK (antibody-cell conjugate NK), ATE-NK (antibody-targeted enhanced NK), and tiNK (trained-immunity NK) in solid and hematological tumors, various non-oncological diseases, and health management.
Imbioray owns cutting-edge patented technology for NK cell immunity training and a world-class large-scale GMP production center. It is an industry standard-setter for the entire chain of NK cell preparation—from raw material collection to release and clinical application. With its high technology, efficiency, and quality, it has become a representative enterprise of national "New Quality Productive Forces."
View More
Dedicated to NK Cell Research
R&D Talents
Honors at Home and Abroad
IND & Biomedical New Technologies
Number and Progress of Clinical Trial Projects
Product Service
ACC-NK (Antibody-cell Conjugate NK) integrates the antigen-targeting function of antibodies and the immune killing function of NK cells through antibody conjugation technology (non-viral vector, non-gene editing). By targeting specific tumor antigens with antibodies, it can quickly and efficiently guide NK cells to recognize and kill tumor cells.
Product Service
ATE-NK (Antibody Targeted Enhanced NK), which stands for antibody-targeted enhanced NK cells, involves the combination of specific antibodies and NK cells to precisely target and eliminate pathologically reactive B/T lymphocytes. Leveraging the "precise navigation" capability of antibodies, it guides NK cells to efficiently exert their cytotoxic effects. Through antibody-dependent cellular cytotoxicity (ADCC), it enhances the killing efficiency of NK cells, achieving the dual efficacy of "targeted clearance + immune regulation". It is expected to become a breakthrough therapy for autoimmune diseases.
Product Service
tiNK® (trained immunity NK) immune-trained NK cells refer to NK cells activated and immunologically trained through specific factors. Training is a cultivation method that simulates the stress conditions faced by NK cells. By utilizing high-intensity cytokines, the killing ability of NK cells is enhanced, just like training a "new recruit of special forces" into a "king of special forces", enabling them to more quickly and effectively eliminate bacteria, viruses, senescent cells, and mutated cells in the human body.
Latest News
金秋九月，奋楫逐新。9月2日，英百瑞（杭州）生物医药股份有限公司携全资子公司杭州百瑞竞康生物技术有限公司、百瑞辉华（杭州）生命健康有限公司，组织全体员工召开全员大会。本次大会全面复盘公司2026年各业务板块阶段性建设成果，深度解码下一阶段战略发展布局，进一步凝聚全员发展共识，提振干事创业奋进动能。2
Learn More2026年9月1日，英百瑞自主研发的核心产品ACC-NK（IBR822）细胞注射液，联合多西他赛用于一线标准治疗失败的晚期非小细胞肺癌患者二线治疗的II期临床试验项目，正式获得国家药品监督管理局临床默示许可，获批进入Ⅱ期临床试验。（通知书编号：2026LP02663、2026LP02664）这是英百
Learn More2026年7月，国际学术期刊《Med》发表了一项由浙江大学医学院附属第二医院联合多家教育部重点实验室共同发表的临床研究成果。同种异体NK细胞疗法在5例难治性系统性红斑狼疮患者中实现了100%的临床缓解，且耐受性良好，无严重不良反应。对于红斑狼疮患者来说，这不是一项普通的科研进展，而是他们有望彻底摆脱
Learn More2026年8月27日，英百瑞ACC-NK（IBR854）细胞注射液联合多西他赛用于一线标准治疗失败的晚期非小细胞肺癌治疗的Ⅱ期临床试验启动会在天津市肿瘤医院顺利召开。这是英百瑞ACC-NK（IBR854）启动在晚期肾细胞癌治疗的Ⅱ期临床试验、联合培美曲塞+顺铂用于局部晚期或转移性非鳞状非小细胞肺癌一
Learn MoreCopyright2026 英百瑞（杭州）生物医药股份有限公司 All Rights Reserved. 浙ICP备2026093145号 KC Network Technology Support
